{{Rsnum
|rsid=5750285
|Chromosome=22
|position=36708203
|Orientation=plus
|GMAF=0.4862
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;G)
| geno3=(G;G)
| CEU | 35.4 | 52.3 | 12.3
| HCB | 31.1 | 42.2 | 26.7
| JPT | 15.9 | 45.5 | 38.6
| YRI | 6.3 | 46.0 | 47.6
| ASW | 0.0 | 0.0 | 0.0
| CHB | 31.1 | 42.2 | 26.7
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs5750285
|Name_s=
|Gene_s=CACNG2
|Feature=
|Evidence=PubMed ID:18408563
|Annotation=The C allele of this variant is associated with increased response of patients with bipolar disorder to lithium treatment relative to that observed in patients carrying two copies of the G allele. This association was seen in one cohort of 195 patients, but not in a separate cohort of 134 patients.
|Drugs=lithium
|Drug Classes=
|Diseases=Bipolar Disorder
|Curation Level=Curated
|PharmGKB Accession ID=PA161659506
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs5750285
|overall_frequency_n=65
|overall_frequency_d=128
|overall_frequency=0.507812
|n_genomes=39
|n_genomes_annotated=0
|n_haplomes=57
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}